Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Cadrenal Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

127636 108

(CUSIP Number)

 

John Raymond Murphy

c/o Cadrenal Therapeutics, Inc.

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(904) 300-0701

(Name, address and telephone number of person authorized to receive notices and communications)

 

With a copy to:

 

Leslie Marlow, Esq.

Blank Rome LLP

1271 Avenue of the Americas

New York, New York 10020

(212) 885-5000

 

March 16, 2023

(Date of event which requires filing of this statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

  

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

  

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 127636 108

SCHEDULE 13G

Page 2 of 5 Pages

 

1	NAME OF REPORTING PERSON
	John Raymond Murphy
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☐
		(b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		594,792
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		594,792
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	594,792 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.11% (2)
12	TYPE OF REPORTING PERSON
	IN

 

(1)

Does not include 100,000 shares of common stock issuable upon the exercise of options held by Mr. Murphy that are not exercisable within 60 days hereof.

(2)

This percentage is calculated based on 11,634,575 of the Common Stock issued and outstanding upon consummation of the Issuer’s initial public offering on January 24, 2023, as reported by the Issuer in the Issuer’s Registration Statement on Form S-1/A, as filed with the Securities and Exchange Commission on January 17, 2023.

 

 

CUSIP No. 127636 108

SCHEDULE 13G

Page 3 of 5 Pages

 

Item 1(a)		Name of Issuer:   Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”)
Item 1(b)		Address of Issuer’s Principal Executive Offices:   822 A1A North, Suite 306 Ponte Vedra, Florida 32082
Item 2(a)		Name of Person Filing:   John Raymond Murphy (sometimes referred to as the “Reporting Person”).
Item 2(b)		Address of Principal Business Office or, if none, Residence:   The address for the principal business office of the Reporting Person is:   c/o Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, Florida 32082
Item 2(c)		Citizenship:   The Reporting Person is a citizen of the United States.
Item 2(d)		Title of Class of Securities:   Common Stock, par value $0.001 per share (“Common Stock”)
Item 2(e)		CUSIP No.:   127636 108

  

Item 3.

If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the Person Filing is:

  

	(a)	☐	Broker or dealer registered under Section 15 of the Exchange Act;
	(b)	☐	Bank as defined in Section 3(a) (6) of the Exchange Act;
	(c)	☐	Insurance company as defined in Section 3(a) (19) of the Exchange Act;
	(d)	☐	Investment company registered under Section 8 of the Investment Company Act;
	(e)	☐	An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);
	(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);
	(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);
	(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
	(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;
	(j)	☐	Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

  

 

CUSIP No. 127636 108

SCHEDULE 13G

Page 4 of 5 Pages

 

Item 4.

Ownership

 

As of the close of business on March 21, 2023, the Reporting Person held an aggregate of 594,792 shares of Common Stock. The Reporting Person also was issued an option to purchase 100,000 shares of Common Stock on July 11, 2022, of which 0 shares have vested and are exercisable within 60 days of the date of this Report.

 

The following sets forth in tabular format the share ownership of each of the Reporting Persons:

 

(a)

Amount beneficially owned:   594,792 shares of Common Stock

 

(b)

Percent of class:   5.11%

 

(c)

Number of shares as to which such person has:

 

	(i)	sole power to vote or to direct the vote:
		594,792 shares
	(ii)	shared power to vote or to direct the vote:
		0 shares
	(iii)	sole power to dispose or to direct the disposition of:
		594,792 shares
	(iv)	shared power to dispose or to direct the disposition of:
		0 shares

 

Item 5.		Ownership of Five Percent or Less of a Class.
		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6.		Ownership of More than Five Percent on Behalf of Another Person.
		Not applicable.
Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
		Not applicable.
Item 8.		Identification and Classification of Members of the Group.
		Not applicable.
Item 9.		Notice of Dissolution of Group.
		Not applicable.
Item 10.		Certifications.
		Not applicable.

  

[signature page follows]

 

 

CUSIP No. 127636 108

SCHEDULE 13G

Page 5 of 5 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

  

Date: March 27, 2023
	/s/ John Raymond Murphy
	John Raymond Murphy